Development of a Robust Scale-Up Synthetic Route for BPR1K871: A Clinical Candidate for the Treatment of Acute Myeloid Leukemia and Solid Tumors
Open Access
- 18 February 2021
- journal article
- research article
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 25 (4), 817-830
- https://doi.org/10.1021/acs.oprd.0c00515
Abstract
No abstract availableKeywords
Funding Information
- National Health Research Institutes
- National Cheng Kung University
- Ministry of Science and Technology, Taiwan (MOST 109-2113-M-400-003)
This publication has 25 references indexed in Scilit:
- How I treat acute myeloid leukemia in the era of new drugsBlood, 2020
- Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 updatePharmacological Research, 2019
- Evolution of Small Molecule Kinase DrugsACS Medicinal Chemistry Letters, 2018
- Discovery of BPR1K871, a quinazoline based, multi-kinase inhibitor for the treatment of AML and solid tumors: Rational design, synthesis, in vitro and in vivo evaluationOncotarget, 2016
- Acute myeloid leukaemia in adultsThe Lancet, 2013
- Optimization of Imidazo[4,5-b]pyridine-Based Kinase Inhibitors: Identification of a Dual FLT3/Aurora Kinase Inhibitor as an Orally Bioavailable Preclinical Development Candidate for the Treatment of Acute Myeloid LeukemiaJournal of Medicinal Chemistry, 2012
- The FLT3 Internal Tandem Duplication Mutation Is a Secondary Target of the Aurora B Kinase Inhibitor AZD1152-HQPA in Acute Myelogenous Leukemia CellsMolecular Cancer Therapeutics, 2010
- Discovery, Synthesis, and in Vivo Activity of a New Class of Pyrazoloquinazolines as Selective Inhibitors of Aurora B KinaseJournal of Medicinal Chemistry, 2007
- Protein Kinase Inhibitors: Insights into Drug Design from StructureScience, 2004
- The Protein Kinase Complement of the Human GenomeScience, 2002